Helicobacter Pylori Eradication Therapy for Immune Thrombocytopenia (ITP) Patients in Iraq

NACompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

March 31, 2025

Study Completion Date

April 1, 2025

Conditions
Immune Thrombocytopenic PurpuraHELICOBACTER PYLORI INFECTIONS
Interventions
DRUG

Levofloxacin-Based H. pylori Eradication Therapy

"This intervention consists of a 14-day levofloxacin-based triple therapy regimen for Helicobacter pylori eradication in ITP patients. The regimen follows current ACG guidelines and typically includes:~Levofloxacin - antibiotic targeting H. pylori~Amoxicillin - antibiotic used in combination for enhanced efficacy~Proton Pump Inhibitor (PPI) - to reduce stomach acid and improve antibiotic effectiveness~Patients will receive the full 14-day course, and platelet counts will be measured at baseline and four weeks post-therapy to assess hematological response. This intervention is unique to H. pylori-positive ITP patients in this study and is not administered to H. pylori-negative patients."

Trial Locations (1)

10001

Al-Mustansiriyah University - college of pharmacy - clinical pharmacy department, Baghdad

All Listed Sponsors
lead

Al-Mustansiriyah University

OTHER

NCT07150286 - Helicobacter Pylori Eradication Therapy for Immune Thrombocytopenia (ITP) Patients in Iraq | Biotech Hunter | Biotech Hunter